KBC Group
ANIP icon

KBC Group’s ANI Pharmaceuticals ANIP Stock Holding History

KBC Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-978
Closed -$81K – 1829
2026
Q2 		$81K Buy
978
+610
+166% +$48.9K ﹤0.01% 1522
2026
Q1 		$28K Buy
+368
New +$28.7K ﹤0.01% 1806
2025
Q2 		– Sell
-1,273
Closed -$85K – 1721
2025
Q1 		$85K Hold
1,273
– – ﹤0.01% 1575
2024
Q4 		$70K Buy
1,273
+600
+89% +$34.4K ﹤0.01% 1729
2024
Q3 		$40K Hold
673
– – ﹤0.01% 1779
2024
Q2 		$43K Hold
673
– – ﹤0.01% 1696
2024
Q1 		$47K Hold
673
– – ﹤0.01% 1589
2023
Q4 		$37K Hold
673
– – ﹤0.01% 1702
2023
Q3 		$39K Sell
673
-408
-38% -$23.5K ﹤0.01% 1635
2023
Q2 		$58K Hold
1,081
– – ﹤0.01% 1327
2023
Q1 		$43K Hold
1,081
– – ﹤0.01% 1412
2022
Q4 		$43K Hold
1,081
– – ﹤0.01% 1426
2022
Q3 		$35K Hold
1,081
– – ﹤0.01% 1458
2022
Q2 		$32K Buy
+1,081
New +$31.2K ﹤0.01% 1491
2020
Q1 		– Sell
-17,006
Closed -$1.05M – 1289
2019
Q4 		$1.05M Hold
17,006
– – 0.01% 882
2019
Q3 		$1.24M Hold
17,006
– – 0.01% 798
2019
Q2 		$1.4M Sell
17,006
-1,290
-7% -$91.7K 0.01% 720
2019
Q1 		$1.29M Sell
18,296
-3,930
-18% -$231K 0.01% 768
2018
Q4 		$1M Sell
22,226
-6,731
-23% -$353K 0.01% 744
2018
Q3 		$1.64M Buy
28,957
+8,598
+42% +$526K 0.01% 756
2018
Q2 		$1.36M Buy
20,359
+4,302
+27% +$269K 0.01% 713
2018
Q1 		$935K Hold
16,057
– – 0.01% 799
2017
Q4 		$1.04M Hold
16,057
– – 0.01% 795
2017
Q3 		$843K Hold
16,057
– – 0.01% 847
2017
Q2 		$751K Buy
16,057
+4,143
+35% +$200K 0.01% 856
2017
Q1 		$590K Buy
11,914
+1,961
+20% +$110K 0.01% 1002
2016
Q4 		$603K Buy
+9,953
New +$609K 0.01% 994

Other funds holding ANIP

Marathon Capital Management
Marathon Capital Management Hunt Valley, Maryland $488M AUM 28.5% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Oliver Luxxe Assets
Oliver Luxxe Assets Gladstone, New Jersey $638M AUM 30.27% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Mitsubishi UFJ Asset Management (UK)
Mitsubishi UFJ Asset Management (UK) London, United Kingdom $213M AUM 36.38% 1-Year Est. Return
Polaris Capital Management
Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return
Kendall Capital Management
Kendall Capital Management Rockville, Maryland $605M AUM 38.16% 1-Year Est. Return
Samalin Investment Counsel
Samalin Investment Counsel Chappaqua, New York $319M AUM 12.97% 1-Year Est. Return

KBC Group's ANIP Position: Q3 2026 in Review

KBC Group sold out of ANI Pharmaceuticals (ANIP) in Q3 2026, closing a stake of 978 shares — an estimated $81K sold.

KBC Group first reported a position in ANIP in Q4 2016 and held it in 27 quarters. The position peaked at $1.64M in Q3 2018. 44 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • KBC Group reported no remaining ANI Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • KBC Group sold 978 ANI Pharmaceuticals shares in Q3 2026, an estimated $81K.
  • KBC Group first reported a position in ANI Pharmaceuticals in Q4 2016 and held it in 27 quarters.
  • KBC Group's ANI Pharmaceuticals position peaked at $1.64M in Q3 2018.
  • 44 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.